Pharmigene Competitors

Stocks . Taiwan . 
Stock . Pharmigene
7595 Stock  TWD 10.05  0.49  5.13%   
Pharmigene competes with UniPharma, Taiwan Advanced, A SPINE, Bioray Biotech, and Welgene Biotech; as well as few others. The company operates under Healthcare sector and is part of Diagnostics & Research industry. Analyzing Pharmigene competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Pharmigene to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Pharmigene Correlation with its peers.

Pharmigene vs 4170 Correlation

Average diversification

The correlation between Pharmigene and 4170 is 0.19 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Pharmigene and 4170 in the same portfolio, assuming nothing else is changed.

Moving against Pharmigene Stock

  0.546579 AAEON TechnologyPairCorr
  0.56615 Sofiva Genomics CoLtdPairCorr
  0.54160 Genetics GenerationPairCorr
  0.46661 Welgene Biotech CoLtdPairCorr
  0.42712 FarGlory HotelPairCorr
Hype
Prediction
LowEstimatedHigh
7.659.5611.47
Details
Intrinsic
Valuation
LowRealHigh
7.869.7711.68
Details
Naive
Forecast
LowNextHigh
7.499.4011.32
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
9.5710.0610.55
Details

Pharmigene Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Pharmigene and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Pharmigene and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Pharmigene does not affect the price movement of the other competitor.

High positive correlations

1781
+ 0.71
7561
1781
+ 0.61
6621
6483
+ 0.61
4115
6483
+ 0.58
6797
6661
+ 0.53
1781
6661
+ 0.51
7561
  

High negative correlations

6483
- 0.62
7561
6483
- 0.6
1781
7561
- 0.43
4115
7561
- 0.43
6797
6483
- 0.4
6661
7561
- 0.34
7607

Risk-Adjusted Indicators

There is a big difference between Pharmigene Stock performing well and Pharmigene Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Pharmigene's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
6621  1.19  0.19  0.08  0.60  1.35 
(1.46)
 3.13 
(2.02)
 9.14 
6797  2.23  0.09  0.00 (0.52) 3.39 
(2.46)
 4.65 
(7.10)
 22.74 
7607  1.72 (0.14) 0.00  2.15  0.00 
 0.00 
 4.63 
(4.65)
 13.34 
4115  1.33  0.04 (0.02) 0.31  1.49 
(2.30)
 3.95 
(3.57)
 8.68 
6758  0.66 (0.09) 0.00 (0.46) 0.00 
 0.00 
 1.62 
(3.97)
 8.78 
7561  2.53  0.67  0.18 (1.88) 2.12 
(3.38)
 6.97 
(4.31)
 14.96 
1781  0.77 (0.04) 0.00 (0.14) 0.00 
 0.00 
 0.91 
(1.33)
 10.60 
6661  0.89 (0.06) 0.00  0.31  0.00 
 0.00 
 2.33 
(2.05)
 7.33 
6483  2.30  0.05 (0.01) 2.65  2.53 
(2.91)
 6.29 
(4.15)
 20.34 
4170  2.16  0.24  0.02 (0.16) 2.26 
(2.53)
 4.44 
(3.62)
 12.49 

Pharmigene Competitive Analysis

The better you understand Pharmigene competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Pharmigene's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Pharmigene's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
7595 6621 6797 7607 4115 6758 7561 1781 6661 6483
 5.13 
 10.05 
Pharmigene
 0.38 
 13.10 
UniPharma
 1.31 
 15.10 
Taiwan
 1.86 
 19.15 
7607
 3.95 
 8.42 
Sunder
 0.52 
 38.50 
6758
 3.85 
 25.00 
Bioray
 0.82 
 12.05 
Health
 1.06 
 19.05 
Welgene
 2.64 
 13.60 
Original
Market Volatility
(90 Days Market Risk)
Not too volatile
Not too volatile
Somewhat reliable
Not too volatile
Somewhat reliable
Very steady
Not too volatile
Not too volatile
Very steady
Somewhat reliable
Market Performance
(90 Days Performance)
Weakest
Good
Weak
Weakest
Weak
Weakest
Good
Weakest
Weakest
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Low
Unknown
Unknown
Low
Low
Fair
Low
Fair
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Sell
Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Sell
Strong Sell
Strong Sell
Current Ratio
14.16
9.6
2.62
N/A
N/A
N/A
3.02
N/A
3.89
N/A
Profit Margin
-11.06
-39.93
33.89
N/A
N/A
N/A
-0.04
N/A
N/A
N/A
EBITDA
(8.73 M)
(15.17 M)
809.69 M
N/A
N/A
N/A
9.36 M
N/A
33.05 M
N/A
Operating Margin
-13.68
-14.87
40.21
N/A
N/A
N/A
-0.14
N/A
N/A
N/A
Current Valuation
717.33 M
286.35 M
945.75 M
N/A
N/A
N/A
725.35 M
N/A
N/A
N/A
Price To Book
2.49
1.23
1.34
N/A
N/A
N/A
2.04
N/A
N/A
N/A
Beta
N/A
1.18
N/A
N/A
N/A
N/A
N/A
N/A
0.33
N/A
Number Of Employees
N/A
42
N/A
N/A
N/A
N/A
79
7
11
8
Shares Outstanding
43.47 M
35.2 M
23.17 M
N/A
N/A
13.47 M
26.73 M
N/A
N/A
N/A
Cash Flow From Operations
(12.78 M)
(17.18 M)
789.25 M
N/A
N/A
N/A
1.67 M
N/A
34.62 M
N/A
Total Debt
21.63 M
16.82 M
553.23 M
N/A
N/A
N/A
61.58 M
N/A
30.42 M
N/A
Return On Equity
-4.15
-14.19
50.59
N/A
N/A
N/A
-0.37
N/A
N/A
N/A
Z Score
28.2
16.2
1.2
N/A
N/A
N/A
7.2
N/A
11.4
N/A
Return On Asset
-2.79
-2.96
19.95
N/A
N/A
N/A
-0.03
N/A
N/A
N/A
Book Value Per Share
9.42
10.77
44.83
N/A
N/A
N/A
13.99
N/A
13.6
N/A
Debt To Equity
0.052
0.044
0.35
N/A
N/A
N/A
0.17
N/A
0.095
N/A
Last Dividend Paid
N/A
N/A
6.0
N/A
N/A
2.5
0.3
N/A
1.1
N/A
Market Capitalization
1.02 B
464.65 M
1.39 B
N/A
N/A
693.76 M
761.86 M
538.08 M
591.92 M
N/A
Price To Earning
N/A
N/A
1.98
N/A
N/A
N/A
53.88
N/A
24.19
N/A
Price To Sales
10.06
3.35
0.74
N/A
N/A
N/A
4.87
N/A
N/A
N/A
Net Income
(11.21 M)
(55.35 M)
636.96 M
N/A
N/A
N/A
(58 K)
N/A
22.38 M
N/A
Earnings Per Share
-0.33
-1.57
30.37
N/A
N/A
N/A
0.53
N/A
1.05
N/A
Revenue
101.35 M
138.64 M
1.88 B
N/A
N/A
N/A
156.3 M
N/A
N/A
N/A
Cash And Equivalents
297.48 M
188.09 M
1.37 B
N/A
N/A
N/A
145.91 M
N/A
239.66 M
N/A
Cash Per Share
6.84
5.34
45.56
N/A
N/A
N/A
5.46
N/A
10.28
N/A
Gross Profit
44.29 M
69.32 M
1.07 B
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Day Typical Price
10.03
13.18
15.02
18.97
8.42
38.48
25.27
12.07
19.05
13.45
Accumulation Distribution
154.48
7246.68
1593.75
2690.53
N/A
2.61
217.29
1290.98
N/A
4006.22
Market Facilitation Index
0.0
0.0
0.0
0.0
N/A
0.0
3.0E-4
0.0
N/A
0.0
Daily Balance Of Power
9.8
(0.09)
(0.24)
0.4667
9.2 T
4.0
(0.83)
(0.40)
9.2 T
0.7778
Period Momentum Indicator
0.49
(0.05)
(0.20)
0.35
0.32
0.2
(1.00)
(0.10)
0.2
0.35
Rate Of Daily Change
1.05
1.0
0.99
1.02
1.04
1.01
0.96
0.99
1.01
1.03
Day Median Price
10.03
13.23
14.98
18.88
8.42
38.48
25.4
12.08
19.05
13.38
Price Action Indicator
0.27
(0.15)
0.025
0.45
0.16
0.13
(0.90)
(0.07)
0.1
0.4
Coefficient Of Variation
(913.57)
698.95
4102.78
(1,913)
2750.12
(2,209)
517.04
(11,059)
(1,744)
5186.25
Mean Deviation
1.44
1.19
2.23
1.72
1.33
0.6586
2.53
0.7732
0.8874
2.3
Jensen Alpha
(0.26)
0.1922
0.0893
(0.14)
0.0418
(0.09)
0.6748
(0.04)
(0.06)
0.0549
Total Risk Alpha
(0.46)
0.0162
(0.37)
(0.47)
(0.18)
(0.24)
0.213
(0.22)
(0.25)
(0.38)
Sortino Ratio
N/A
0.0758
(0)
N/A
(0.02)
N/A
0.1786
N/A
N/A
(0.01)
Downside Variance
N/A
3.1
17.87
N/A
4.75
N/A
9.43
N/A
N/A
7.57
Standard Deviation
1.91
1.66
3.52
2.58
1.92
1.34
3.37
1.53
1.29
3.47
Kurtosis
(0.20)
1.64
3.23
2.87
0.4731
6.91
1.25
25.99
1.68
6.0
Potential Upside
3.43
3.13
4.65
4.63
3.95
1.62
6.97
0.9132
2.33
6.29
Treynor Ratio
(0.46)
0.6041
(0.52)
2.15
0.313
(0.46)
(1.88)
(0.14)
0.3144
2.65
Maximum Drawdown
7.09
9.14
22.74
13.34
8.68
8.78
14.96
10.6
7.33
20.34
Variance
3.66
2.76
12.38
6.67
3.67
1.79
11.39
2.34
1.66
12.04
Market Risk Adjusted Performance
(0.45)
0.6141
(0.51)
2.16
0.323
(0.45)
(1.87)
(0.13)
0.3244
2.66
Risk Adjusted Performance
(0.07)
0.1112
0.0259
(0.03)
0.033
(0.03)
0.1506
(0)
(0.04)
0.0221
Skewness
0.1131
0.1936
0.1631
0.8562
0.1939
(0.81)
0.7798
4.1
0.475
1.72
Semi Deviation
N/A
1.35
3.39
N/A
1.49
N/A
2.12
N/A
N/A
2.53
Information Ratio
(0.16)
0.0804
(0.01)
(0.09)
(0.02)
(0.12)
0.1626
(0.08)
(0.14)
(0.01)
Value At Risk
(3.82)
(2.02)
(7.10)
(4.65)
(3.57)
(3.97)
(4.31)
(1.33)
(2.05)
(4.15)
Expected Short fall
N/A
(1.46)
(2.46)
N/A
(2.30)
N/A
(3.38)
N/A
N/A
(2.91)
Downside Deviation
N/A
1.76
4.23
N/A
2.18
N/A
3.07
N/A
N/A
2.75
Semi Variance
N/A
1.82
11.48
N/A
2.21
N/A
4.5
N/A
N/A
6.42

Pharmigene Competition Performance Charts

Five steps to successful analysis of Pharmigene Competition

Pharmigene's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Pharmigene in relation to its competition. Pharmigene's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Pharmigene in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Pharmigene's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Pharmigene, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Pharmigene position

In addition to having Pharmigene in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Sport Products Thematic Idea Now

Sport Products
Sport Products Theme
Companies manufacturing sporting goods and accessories. The Sport Products theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sport Products Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Pharmigene Stock Analysis

When running Pharmigene's price analysis, check to measure Pharmigene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmigene is operating at the current time. Most of Pharmigene's value examination focuses on studying past and present price action to predict the probability of Pharmigene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmigene's price. Additionally, you may evaluate how the addition of Pharmigene to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY